1. Home
  2. SEI vs AVBP Comparison

SEI vs AVBP Comparison

Compare SEI & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEI
  • AVBP
  • Stock Information
  • Founded
  • SEI 2014
  • AVBP 2021
  • Country
  • SEI United States
  • AVBP United States
  • Employees
  • SEI N/A
  • AVBP N/A
  • Industry
  • SEI
  • AVBP
  • Sector
  • SEI
  • AVBP
  • Exchange
  • SEI NYSE
  • AVBP NYSE
  • Market Cap
  • SEI 1.1B
  • AVBP 948.5M
  • IPO Year
  • SEI 2017
  • AVBP 2024
  • Fundamental
  • Price
  • SEI $26.87
  • AVBP $26.09
  • Analyst Decision
  • SEI Strong Buy
  • AVBP Strong Buy
  • Analyst Count
  • SEI 2
  • AVBP 5
  • Target Price
  • SEI $30.00
  • AVBP $36.80
  • AVG Volume (30 Days)
  • SEI 889.9K
  • AVBP 169.6K
  • Earning Date
  • SEI 02-16-2025
  • AVBP 02-02-2025
  • Dividend Yield
  • SEI 1.79%
  • AVBP N/A
  • EPS Growth
  • SEI N/A
  • AVBP N/A
  • EPS
  • SEI 0.43
  • AVBP N/A
  • Revenue
  • SEI $280,141,000.00
  • AVBP N/A
  • Revenue This Year
  • SEI $9.54
  • AVBP N/A
  • Revenue Next Year
  • SEI $64.93
  • AVBP N/A
  • P/E Ratio
  • SEI $62.32
  • AVBP N/A
  • Revenue Growth
  • SEI N/A
  • AVBP N/A
  • 52 Week Low
  • SEI $6.59
  • AVBP $14.35
  • 52 Week High
  • SEI $32.61
  • AVBP $36.37
  • Technical
  • Relative Strength Index (RSI)
  • SEI N/A
  • AVBP 40.46
  • Support Level
  • SEI N/A
  • AVBP $25.01
  • Resistance Level
  • SEI N/A
  • AVBP $27.66
  • Average True Range (ATR)
  • SEI 0.00
  • AVBP 1.39
  • MACD
  • SEI 0.00
  • AVBP -0.22
  • Stochastic Oscillator
  • SEI 0.00
  • AVBP 20.93

About SEI SOLARIS ENERGY INFRASTRUCTURE INC

Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution.

About AVBP ARRIVENT BIOPHARMA INC

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Share on Social Networks: